Chng WJ - Search Results

1

Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).

Rashid MBMA, Toh TB, Hooi L, Silva A, Zhang Y, Tan PF, Teh AL, Karnani N, Jha S, Ho CM, Chng WJ, Ho D, Chow EK. Rashid MBMA, et al. Among authors: chng wj. Sci Transl Med. 2018 Aug 8;10(453):eaan0941. doi: 10.1126/scitranslmed.aan0941. Sci Transl Med. 2018. PMID: 30089632

2

Targeted therapy in multiple myeloma.

Chng WJ, Lau LG, Yusof N, Mow BM. Chng WJ, et al. Cancer Control. 2005 Apr;12(2):91-104. doi: 10.1177/107327480501200204. Cancer Control. 2005. PMID: 15855892 Free article. Review.

3

Determinants of sensitivity to DZNep induced apoptosis in multiple myeloma cells.

Xie Z, Bi C, Cheong LL, Liu SC, Huang G, Zhou J, Yu Q, Chen CS, Chng WJ. Xie Z, et al. Among authors: chng wj. PLoS One. 2011;6(6):e21583. doi: 10.1371/journal.pone.0021583. Epub 2011 Jun 24. PLoS One. 2011. PMID: 21720561 Free PMC article.

4

miRNA deregulation in multiple myeloma.

Bi CL, Chng WJ. Bi CL, et al. Among authors: chng wj. Chin Med J (Engl). 2011 Oct;124(19):3164-9. Chin Med J (Engl). 2011. PMID: 22040573 Review.

5

Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse model.

Siveen KS, Mustafa N, Li F, Kannaiyan R, Ahn KS, Kumar AP, Chng WJ, Sethi G. Siveen KS, et al. Among authors: chng wj. Oncotarget. 2014 Feb 15;5(3):634-48. doi: 10.18632/oncotarget.1596. Oncotarget. 2014. PMID: 24504138 Free PMC article.

6

MicroRNA: important player in the pathobiology of multiple myeloma.

Bi C, Chng WJ. Bi C, et al. Among authors: chng wj. Biomed Res Int. 2014;2014:521586. doi: 10.1155/2014/521586. Epub 2014 Jun 3. Biomed Res Int. 2014. PMID: 24991558 Free PMC article. Review.

7

MMSET: role and therapeutic opportunities in multiple myeloma.

Xie Z, Chng WJ. Xie Z, et al. Among authors: chng wj. Biomed Res Int. 2014;2014:636514. doi: 10.1155/2014/636514. Epub 2014 Jul 1. Biomed Res Int. 2014. PMID: 25093175 Free PMC article. Review.

8

Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma.

Bi C, Chung TH, Huang G, Zhou J, Yan J, Ahmann GJ, Fonseca R, Chng WJ. Bi C, et al. Among authors: chng wj. Oncotarget. 2015 Sep 22;6(28):26508-18. doi: 10.18632/oncotarget.4769. Oncotarget. 2015. PMID: 26164366 Free PMC article.

9

Epigenetic silencing of EVL/miR-342 in multiple myeloma.

Li Z, Wong KY, Chan GC, Chng WJ, Chim CS. Li Z, et al. Among authors: chng wj. Transl Res. 2018 Feb;192:46-53. doi: 10.1016/j.trsl.2017.11.005. Epub 2017 Nov 23. Transl Res. 2018. PMID: 29242101

10

Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis.

Teoh PJ, An O, Chung TH, Chooi JY, Toh SHM, Fan S, Wang W, Koh BTH, Fullwood MJ, Ooi MG, de Mel S, Soekojo CY, Chen L, Ng SB, Yang H, Chng WJ. Teoh PJ, et al. Among authors: chng wj. Blood. 2018 Sep 20;132(12):1304-1317. doi: 10.1182/blood-2018-02-832576. Epub 2018 Jul 30. Blood. 2018. PMID: 30061158 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

375 results

Search Page